GlassScriptPhysician profile
Edward Alan Nabrinsky
NPI 1871099754
$8,374.46
in general payments reported to CMS, 2019-2025
55 companies · $6,706 in 2025
The $6,706 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $78.28 · 2024: $1,468 · 2025: $6,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,006 · Consulting Fee: $2,480 · Long Term Medical Supply Or Device Loan: $499 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,006.25 |
| Consulting Fee | $2,480.00 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $189.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $2,524.97 | 2024-2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $927.80 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $609.71 | 2024-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Biotech, INC. | $367.27 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $280.72 | 2024-2025 | Cresemba, Padcev, Xtandi |
| Genentech USA, INC. | $256.66 | 2024-2025 | Itovebi, Venclexta, Tecentriq |
| Tempus Ai, INC | $251.57 | 2025 | Xt Cdx |
| Array Biopharma INC | $226.52 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Lilly USA, LLC | $217.29 | 2021-2025 | |
| Abbvie INC. | $210.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $192.40 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $180.50 | 2024-2025 | |
| Incyte Corporation | $167.80 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| Eisai INC. | $150.46 | 2024-2025 | |
| Glaxosmithkline, LLC. | $127.95 | 2024-2025 | Jemperli, Zejula, Ojjaara |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $112.92 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $104.85 | 2024-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $103.66 | 2024-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $86.68 | 2025 | Monoferric |
| Adc Therapeutics America, INC. | $78.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.44 | 2024-2025 | Fruzaqla, Iclusig |
| Taiho Oncology, INC. | $66.54 | 2025 | |
| Genzyme Corporation | $61.39 | 2024-2025 | |
| Tersera Therapeutics LLC | $58.15 | 2024-2025 | Zoladex |
| Beone Medicines USA, INC. | $52.31 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $51.29 | 2025 | Enhertu |
| Geron Corporation | $50.91 | 2025 | Rytelo |
| Gilead Sciences, INC. | $50.40 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $40.03 | 2025 | Opdualag, Opdivo |
| Aveo Pharmaceuticals, INC. | $38.40 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $37.86 | 2025 | Orgovyx |
| Beigene USA, INC. | $37.29 | 2024-2025 | Tevimbra, Brukinsa |
| Caris Mpi, INC. | $35.68 | 2025 | Mi Cancer Seek |
| Pharmaand Gmbh | $34.48 | 2025 | Rubraca |
| Tolmar, INC. | $34.48 | 2025 | Rubraca, Eligard |
| Genmab U.S., INC. | $34.24 | 2024-2025 | Epkinly |
| Blueprint Medicines Corporation | $33.47 | 2024-2025 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $33.47 | 2024-2025 | Vivimusta, Danziten |
| Puma Biotechnology, INC. | $33.45 | 2024-2025 | |
| Amgen INC. | $32.72 | 2025 | |
| Emd Serono, INC. | $28.05 | 2025 | |
| Karyopharm Therapeutics INC. | $24.73 | 2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.57 | 2024 | |
| Fennec Pharmaceuticals, INC. | $22.46 | 2024 | Pedmark |
| Nuvation Bio INC. | $22.27 | 2025 | Ibtrozi |
| Kite Pharma, INC. | $21.46 | 2025 | Yescarta |
| Accord Healthcare, INC. | $20.76 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.47 | 2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $19.94 | 2025 | Gomekli |
| Ferring Pharmaceuticals INC. | $19.85 | 2025 | Adstiladrin |
| Rigel Pharmaceuticals, INC. | $18.11 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Melinta Therapeutics, LLC | $17.83 | 2024 | Orbactiv, Rezzayo |
| Jazz Pharmaceuticals INC. | $17.72 | 2025 | |
| Coherus Oncology, INC. | $15.66 | 2025 | Loqtorzi |
| Novocure INC. | $15.39 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Nabrinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.